Join the fierce
FIERCE-HN—Phase 3 study of an investigational medicine as potential treatment for advanced head and neck cancer
Not actual patient
Not actual patient
Looking for an open clinical study?
FIERCE-HN is a Phase 3 study of ficlatuzumab
Clinical studies are essential to advancing the science of medicine and improving treatment outcomes. Study participants are key to finding new treatment options for diseases such as cancer. The FIERCE-HN study will enroll people with recurrent or metastatic human papillomavirus (HPV)-negative head and neck squamous cell carcinoma who will be treated with an already approved drug (cetuximab), with or without a second drug, ficlatuzumab, which is under investigation.
Select a section of this website to learn more about the FIERCE-HN study and whether it might be an option for you or someone under your care.
Not actual patient
FOR PEOPLE CONSIDERING ENROLLING IN THE STUDY
Not actual HCP
FOR HEALTHCARE PROFESSIONALS
Michael Bailey, President and CEO of AVEO Oncology, talks about clinical research
Michael Bailey discusses the AVEO Oncology commitment to people and science. AVEO Oncology makes good on this commitment by investing in clinical trials and exploring the potential of new medications to improve the unmet treatment needs of people with cancer.
Michael Bailey, President and CEO of AVEO Oncology, talks about clinical research
Michael Bailey discusses the AVEO Oncology commitment to people and science. AVEO Oncology makes good on this commitment by investing in clinical trials and exploring the potential of new medications to improve the unmet treatment needs of people with cancer.
Being part of a clinical trial helps get new therapies to more people and helps improve cancer treatments. We’d like to recognize all our clinical trial participants—past, present, and future—for their selfless commitment to helping others. Without your help, our efforts to pursue treatments that improve the lives of those with cancer would be far less effective.
Thank you.
NCT06064877:
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Not actual patient
Not actual patient